A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)

NCT02774239 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Myasthenia Gravis

Interventions

DRUG: Human normal immunoglobulin G (IgG)

Sponsor

University of Alberta

Collaborators

[object Object]